Darzalex

Active Ingredient(s): Daratumumab
FDA Approved: * November 16, 2015
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Darzalex Overview

Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38,[1] which multiple myeloma cells overexpress.[2] Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.[3] Daratumumab was given breakthrough therapy drug status in 2013 for multiple myeloma. I...

Read more Darzalex Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daratumumab

Recent Darzalex Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Darzalex: (1 result)

Sorted by National Drug Code

• 57894-502 Darzalex 100 mg/5ml Intravenous Injection, Solution, Concentrate by Janssen Biotech, Inc.

Other drugs which contain Daratumumab or a similar ingredient: (3 results)

• DARATUMUMAB
• DARATUMUMAB + HYALURONIDASE
• DARZALEX FASPRO Daratumumab + Hyaluronidase-fihj